CO5670356A2 - Programa de dosificaicon para un nuevo agente anticanceroso - Google Patents

Programa de dosificaicon para un nuevo agente anticanceroso

Info

Publication number
CO5670356A2
CO5670356A2 CO06015089A CO06015089A CO5670356A2 CO 5670356 A2 CO5670356 A2 CO 5670356A2 CO 06015089 A CO06015089 A CO 06015089A CO 06015089 A CO06015089 A CO 06015089A CO 5670356 A2 CO5670356 A2 CO 5670356A2
Authority
CO
Colombia
Prior art keywords
inhibitor
new anti
mammal
interval
procedure
Prior art date
Application number
CO06015089A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitseh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5670356A2 publication Critical patent/CO5670356A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Un procedimiento para tratar la sobreexpresión del receptor de erbB2 en un mamífero que necesite dicho tratamiento, comprendiendo dicho procedimiento: (a) administrar a dicho mamífero una cantidad terapéuticamente eficaz de un primer inhibidor del receptor de erbB2; y (b) administrar posteriormente a dicho mamífero, después de un intervalo que comprende menos de 24 horas, de una a seis cantidades terapéuticamente eficaces de un segundo inhibidor del receptor de erbB2.2.- El procedimiento de la reivindicación 1, en el que se administra una cantidad terapéuticamente eficaz de dicho segundo inhibidor del receptor de erbB2 en la etapa (b) de dicho procedimiento.3.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que intervalo de la etapa (b) de dicho procedimiento es menor de 12 horas.4.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que intervalo de la etapa (b) de dicho procedimiento es menor de 1 hora.5.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que el primer inhibidor en (a) es el mismo que el segundo inhibidor en (b).
CO06015089A 2003-08-18 2006-02-15 Programa de dosificaicon para un nuevo agente anticanceroso CO5670356A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
CO5670356A2 true CO5670356A2 (es) 2006-08-31

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06015089A CO5670356A2 (es) 2003-08-18 2006-02-15 Programa de dosificaicon para un nuevo agente anticanceroso

Country Status (18)

Country Link
US (1) US20050119288A1 (es)
EP (1) EP1658080A1 (es)
JP (1) JP2007502807A (es)
KR (2) KR20060037447A (es)
CN (1) CN1838959A (es)
AR (1) AR045268A1 (es)
AU (1) AU2004264726A1 (es)
BR (1) BRPI0413745A (es)
CA (1) CA2536140A1 (es)
CO (1) CO5670356A2 (es)
IL (1) IL173127A0 (es)
MX (1) MXPA06001989A (es)
NO (1) NO20061252L (es)
RU (1) RU2328287C2 (es)
SG (1) SG135193A1 (es)
TW (1) TW200522966A (es)
WO (1) WO2005016347A1 (es)
ZA (1) ZA200600517B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CN1972688B (zh) * 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
WO2006129163A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
KR20080027253A (ko) * 2005-06-16 2008-03-26 미리어드 제네틱스, 인크. 약제학적 조성물 및 이의 용도
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
PT1971601E (pt) * 2005-11-15 2010-01-26 Array Biopharma Inc Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF TUMORS EXPRESSING EGF MUTANT RECEPTORS
RU2008143554A (ru) * 2006-04-05 2010-05-10 Новартис АГ (CH) Комбинации терапевтических агентов для лечения рака
AU2007319825B2 (en) 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
NZ580866A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating brain cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
EP2408817B1 (en) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Bispecific anti-her antibodies
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN109652295A (zh) * 2014-01-31 2019-04-19 凸版印刷株式会社 生物分子分析试剂盒及生物分子分析方法
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
JP4202926B2 (ja) * 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用
AU2003291394B2 (en) * 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
BR0317433A (pt) * 2002-12-18 2005-11-16 Pfizer Prod Inc Derivados bicìclicos para o tratamento do crescimento celular anormal

Also Published As

Publication number Publication date
WO2005016347A1 (en) 2005-02-24
EP1658080A1 (en) 2006-05-24
AU2004264726A1 (en) 2005-02-24
KR20080014144A (ko) 2008-02-13
BRPI0413745A (pt) 2006-10-24
KR20060037447A (ko) 2006-05-03
CA2536140A1 (en) 2005-02-24
MXPA06001989A (es) 2006-05-17
RU2006102125A (ru) 2007-09-27
NO20061252L (no) 2006-05-16
JP2007502807A (ja) 2007-02-15
CN1838959A (zh) 2006-09-27
US20050119288A1 (en) 2005-06-02
ZA200600517B (en) 2007-02-28
IL173127A0 (en) 2006-06-11
RU2328287C2 (ru) 2008-07-10
AR045268A1 (es) 2005-10-19
SG135193A1 (en) 2007-09-28
TW200522966A (en) 2005-07-16

Similar Documents

Publication Publication Date Title
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
ECSP056156A (es) Procedimiento y composiciones farmacéuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
AR060089A1 (es) Tratamiento del dolor
PE20080349A1 (es) Estructuras de cristal de inhibidores sglt2 y procesos para preparar los mismos
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
CO5590913A2 (es) Terapia de combinacion antivirica
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
RS53491B1 (en) Compositions for the treatment of centrally mediated nausea and vomiting
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
EA200101089A1 (ru) Новый способ лечения
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза

Legal Events

Date Code Title Description
FC Application refused